Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients. by Mahmoodnia, Leila. et al.
Journal of Renal Injury Prevention
J Renal Inj Prev. 2017; 6(2): 88-92.
Relationship between serum irisin, glycemic indices, 
and renal function in type 2 diabetic patients
*Corresponding author: Marzieh Kafeshani, Email: marzikafeshani@hlth.mui.ac.ir
http://journalrip.com                DOI: 10.15171/jrip.2017.17
Leila Mahmoodnia1, Maryam Sadoughi1, Ali Ahmadi2, Marzieh Kafeshani3*
1Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran 
2Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran
3School of Nutrition & Food Science, Isfahan University of Medical Sciences, Isfahan, Iran
Introduction
The worldwide prevalence of diabetes was estimated 382 
million people by the International Diabetes Federation in 
2013. Diabetes mellitus is a complex public health concern 
that is related with various micro-vascular (neuropathy, 
nephropathy, and retinopathy) and macro-vascular 
(peripheral arterial disease, coronary artery disease, and 
stroke) complications. These complications cause vast 
disability, morbidity, and mortality, and even low quality 
of life. There are different factors that influence on the risk 
of developing diabetes and its complication (1).
Recently, researchers have shown an increased interest 
in association between irisin level and diseases. Irisin is a 
novel peptide that plays notable role in human and animal 
biology and physiology. It has been reported that irisin 
may improve body weight states and insulin resistance. 
Irisin was first introduced as exercise-induced myokines 
by Boström et al in 2012, but other studies showed it also 
is an adipokine that secreted by subcutaneous adipocytes 
and affected by exercise and nutritional factors (2). In 
brief, Boström et al demonstrated that exercise enhances 
levels of peroxisome proliferator-activated receptor-γ 
coactivator-1α (PGC-1α) in the muscle thus the expression 
of the type I membrane precursor protein fibronectin-type 
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Introduction: Irisin is a novel peptide that plays notable role in human and animal biology 
and physiology. It has been reported that irisin may improve insulin resistance and related 
disturbances. 
Objectives: The aim of this investigation was to assess the relationship between serum irisin, 
glycemic indices, and renal function in diabetic subjects.
Patients and Methods: In this cross-sectional study, a total of 102 type 2 diabetes mellitus 
(T2DM) patients were recruited. Blood biochemical parameters, including fasting plasma 
sugar (FBS), glycosylated hemoglobin (HbA1C), serum uric acid (sUA), creatinine concentration 
and glomerular filtration rate (GFR) were measured. All statistical analysis was performed 
with SPSS 16.0.
Results: There was a positive correlation between irisin and age (P = 0.05, r= 0.19) and a 
negative correlation between irisin and body mass index (BMI) (P = 0.01, r= -0.25) was 
detected. There was a significant difference of serum irisin level between patients with normal 
and abnormal FBS too.
Conclusion: In this study we found, irisin concentration was increased with age, decreased 
with BMI, and it was higher in subject with abnormal FBS. Thus further research is needed 
to provide inclusive understanding of irisin associated physiological effects and possible 
implications in clinical conditions.
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III domain-containing 5 (FNDC5) was induced. Then 
irisin was produced by attaching N-terminal fibronectin 
III (FNIII)-like domain to a flexible C-terminal. Irisin 
stimulated the expression of brown adipose tissue (BAT) 
related genes such as uncoupling protein 1 (UCP1, highly 
expressed in BAT and a marker of browning), partially 
through increased PPAR–α and other incompletely 
understood method (3). Lesser circulating irisin was 
related with the insulin resistance, diabetes (4,5), chronic 
kidney disease (6,7) and other disease (8). The results 
of studies on irisin and glucose homeostasis have been 
controversial. Some studies established that serum irisin 
was significantly negatively correlated with hemoglobin 
A1C, fasting blood glucose, 2 hours plasma glucose and 
homeostasis model assessment of insulin resistance 
(HOMA-IR) and other studies found positive correlation 
(9). Studies regarding relationship between serum irisin 
and renal functional markers are scares however these 
researches suggested that irisin level might be associated 
with renal function in humans. 
Objectives
According to the limited studies and the controversy 
about scientific evidence, there is a need for further 
research to identify the relationship between irisin, and 
clinical and biochemical markers of various chronic 
diseases. The main aim of this investigation was to assess 
the relationship between serum irisin, glycemic indices, 
and renal function in diabetic individuals.
Patients and Methods
Patients
In this cross-sectional study, a total of 102 type 2 diabetes 
mellitus (T2DM) patients were recruited from Imam-
Ali clinic, Shahrekord, Iran. In the present study, T2DM 
was defined using the American Diabetes Association 
(ADA) criteria. Standard questionnaire was used for 
assessing information, including age, sex, disease history, 
anti-diabetic and anti-hypertensive drugs. Diabetic 
patients on dialysis, patients with kidney transplants, 
and mentally retarded patients who were not able to give 
informed consent were excluded. Additionally patients 
with malignancy and active or chronic infections were 
excluded.
Ethical issues
The research adhered to the principles of the Declaration 
of Helsinki; the purpose and design of study were explained 
for all subjects and they completed an informed consent 
form. Ethical Committee of Shahrekord University of 
Medical Science approved the protocol (#IR.SKUMS.REC 
1394.165).
Biochemical assessments
Blood biochemical parameters, including fasting plasma 
sugar (FBS), serum uric acid (sUA) and creatinine (Cr)
concentration were measured by commercially available 
enzyme assay kits (Pars Azmon kit, Iran). HbA1C was 
measured with chromatography using Biosystem kit 
(Spain). Glomerular filtration rate (GFR) was estimated 
from the results of blood Cr test and by the Modification 
of Diet in Renal Disease (MDRD) equation. Circulating 
irisin was quantified using a commercial ELISA kit 
(BioVendor – Laboratorni Medicina, Czech Republic). 
Clinical measurements
Blood pressure (BP) was determined in a seated position 
where their arm sustained at heart level, after 5 minute 
rest. BP was noted as three sequential amounts at intervals 
of 30 seconds. The mean of the three BP measurements 
was utilized in the analysis. 
Statistical analysis
The normality of data was tested by using Kolmogorov-
Smirnov test. The nonparametric statistical methods 
were used to analyses the numerical data because the 
data had no normal distribution. Parametric variables 
were extracted as mean ± standard deviation (SD). 
Categorical data were stated as percent and compared 
by χ2 test. Median and quartile were used to describe 
nonparametric data. Mann–Whitney U rank test was used 
to compare differences between groups. Kruskal–Wallis 
one-way analysis of variance test was used to compare 
irisin between different levels of body mass index (BMI). 
Spearman’s correlation coefficient and partial correlation 
tests were applied to evaluate the correlation between 
nonparametric variables. The data were analyzed by SPSS 
version 16. In this study, P value below 0.05 was respected 
as statistically significant for all tests.
Results
Table 1 illustrates some of the main characteristics of 
the subjects. The mean age was 61.25 ± 11.7 years. The 
majority of subjects were women (68% of total), and 
duration of diabetes was 7.64 years.
The results of the correlational analysis are presented in 
Table 2. In this study a positive correlation between serum 
irisin and age (P = 0.05, r = 0.19) and a negative correlation 
between irisin and BMI was detected (P = 0.01, r = -0.25). 
Accordingly a positive correlation between age and serum 
Cr (P = 0.02, r = 0.23) was detected.
Spearman’s correlation analysis was performed to study the 
correlation between variables. The association between 
circulating irisin and biochemical and demographic 
parameters was shown in Tables 3 and 4. Data from both 
tables shows that, the majority of individuals had normal 
FBS (mg/dL), HbA1C (%), and GFR, however sUA (mg/
dL) and sCr (mg/dL) in the most of them were abnormal. 
There was a significant difference in serum irisin level 
between patients with normal and abnormal FBS (mg/
dL), but there was no significant differences in irisin 
level between subjects with normal and abnormal other 
biochemical parameters. Also there was no significant 
difference between men and women and patients who 
taking insulin or oral hypoglycemic agents.
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Discussion
The present study was designed to determine relationship 
between serum irisin, glycemic indices, and renal function 
in diabetic patients. The results of this study indicated a 
positive correlation between irisin and age and a negative 
correlation between irisin and BMI. We also found a 
marginally negative correlation between irisin and FBS. 
However no significant correlation between circulating 
irisin and HbA1c was detected. There was a significant 
difference in serum irisin level between the subject with 
normal and abnormal FBS, so it can be concluded that 
circulating irisin was higher in diabetic subjects with 
uncontrolled FBS. These results are consistent with other 
studies. Huh et al found circulating irisin concentrations 
were positively correlated with FBS (5) and Mehrabian 
et al determined serum irisin level correlated positively 
with insulin levels and FBS in normal weight obese 
subjects (10). Also Liu et al demonstrated the positive 
correlation between circulating irisin and FBS in non-
obese, non-diabetic individuals. These results differ from 
some published studies (7). Zhang et al and Du et al in 
two different meta-analysis established that circulating 
irisin concentrations were significantly lower in patients 
with T2DM (4,11). Sanchis-Gomar et al reported positive 
correlation between irisin level and HbA1c in T2DM 
patients with and without obesity (12). While, the majority 
of subjects were obese or over weight hence one explanation 
Table 1. Basic characteristics of diabetic subjects (n = 103)
Mean or medianc SD or range
Age (years) 61.25 11.70
BMI (kg/m2) 29.32 5.48
Male (%) 32
Types of drug (%)
 Insulin 10.9 -
 Oral hypoglycemic agents 89.1 -
Duration of diabetes (years) 7.64 0.61
FBS (mg/dL) 140 109-183
HbA1c (%) 7.50 6.10-9.00
sUA (mg/dL) 4.70 3.95-5.60
Cr (mg/dL) 0.90 0.80-1.00
eGFRa (mL/min/1.73 m2) 83.70 64.45-100.83
GFR (MDRD)b (cc/min) 72.07 63.39-83.21
Irisin (ng/dL) 2.60 1.80-3.40
Abbreviations: BMI, body mass index; FBS, fasting blood sugar; HbA1c, 
glycosylated hemoglobin; sUA, serum uric acid; Cr, creatinine.
a eGFR (estimated glomerular filtration rate) calculated from the results 
of blood creatinine, age, body size and gender.
b GFR (MDRD), calculated from the Modification of Diet in Renal Disease 
(MDRD) equation. Data for categorical variables are presented as 
percentages. 
c Parametric and non-parametric variables were extracted as mean ± SD 
and median, quartile respectively.
Table 2. Correlation between serum irisin, glycemic indices, and renal function in diabetic patients
Irisin Age sUA    sCr eGFR GFR FBS HbA1c HTN BMI
Irisin 0.19a 0.01 -0.01 -0.14 0.01 -0.18b -0.09 -0.07 -0.25a
Age 0.1 0.23a -0.66a -0.4a -0.07 -0.09 -0.13 -0.18
sUA 0.44a -0.14 -0.37a -0.16 -0.27a 0.11 0.24a
Cr -0.46a -0.74a -0.07 -0.01 -0.07 0.03
GFR (mL/min/1.73 m2) 0.72a 0.05 -0.08 0.19 0.54a
GFR (MDRD) (cc/min) 0.08 0.01 0.29a 0.05
FBS 0.55a 0.16 -0.1
HbA1c 0.16 -0.18
Abbreviations: BMI, body mass index; FBS, fasting blood sugar; HbA1c, glycosylated hemoglobin; sUA, serum uric acid; sCr, serum creatinine.
eGFR, estimated glomerular filtration rate; HTN, hypertension; MDRD, Modification of Diet in Renal Disease.
a P < 0.05 is significant; b is marginally significant.
Table 3. Compare circulating irisin between diabetic subjects with normal and abnormal biochemical characteristics
Normal Abnormal
P value
Percent Mean (ng/dL) SD Percent Mean (ng/dL) SD
sUA (mg/dL) 85.1 2.98 0.22 14.9 2.86 0.21 0.71
Cr (mg/dL) 95 2.86 0.15 5 3.2 0.49 0.37
eGFR (mL/min/1.73 m2) 39.6 2.67 1.18 60.4 3.10 1.81 0.29
GFR (MDRD) 10.9 2.88 1.84 89.1 2.94 1.58 0.37
FBS (mg/dL) 89.1 2.81 1.55 10.9 3.92 1.73 0.009
HbA1c (%) 43.6 2.87 1.37 56.4 2.98 1.77 0.84
Abbreviations: FBS, fasting blood sugar; HbA1c, glycosylated hemoglobin; sUA, serum uric acid; Cr, creatinine; eGFR, estimated glomerular filtration 
rate; MDRD, Modification of Diet in Renal Disease.
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for our result is “irisin resistance” in obese people as same 
as leptin and insulin resistance (13). Our findings revealed 
that no correlation between irisin and renal function 
tests and indices such as sUA, Cr, and GFR was detected. 
Also no significant difference between the subjects with 
normal and abnormal renal function markers was seen. 
The findings of the current study do not support the 
previous research (6,7), while, Wen et al established that 
plasma irisin levels were significantly decreased in chronic 
kidney disease (CKD) patients (6,7). Accordingly, Liu et 
al found that circulating irisin was significantly decreased 
in diabetic patients with renal insufficiency compared to 
T2DM patients with normal renal function. They found 
that circulating irisin was independently associated with 
GFR (7). Yang et al determined that high serum irisin level 
was associated with reduced risk of chronic kidney disease 
(CKD) (14). A possible explanation for this inconsistency 
may be due to studied different populations. 
Conclusion
This study presented the relationship between serum irisin, 
glycemic indices, and renal function in diabetic subjects. 
This research has shown a positive correlation between 
irisin and age and a negative correlation between irisin 
and BMI (P = 0.01, r = -0.25). We also showed a significant 
difference in serum irisin level between the subjects with 
normal and abnormal FBS. In general, it seems that serum 
irisin concentration was increased with age and decreased 
with BMI and it was higher in subject with abnormal 
FBS. However, further research is suggested to provide 
inclusive understanding of irisin associated physiological 
effects and possible implications in clinical conditions.
Limitations of the study
Low proportion of patients is a limitation of our study.
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